{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:05:38Z","timestamp":1787501138025,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.ppat.1012456","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000}}],"reference-count":120,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV004923"],"award-info":[{"award-number":["INV004923"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI44462"],"award-info":[{"award-number":["UM1AI44462"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI170928"],"award-info":[{"award-number":["R01AI170928"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["OD011132"],"award-info":[{"award-number":["OD011132"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["OD026799"],"award-info":[{"award-number":["OD026799"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    The continued evolution of SARS-CoV-2 variants capable of subverting vaccine and infection-induced immunity suggests the advantage of a broadly protective vaccine against betacoronaviruses (\u03b2-CoVs). Recent studies have isolated monoclonal antibodies (mAbs) from SARS-CoV-2 recovered-vaccinated donors capable of neutralizing many variants of SARS-CoV-2 and other \u03b2-CoVs. Many of these mAbs target the conserved S2 stem region of the SARS-CoV-2 spike protein, rather than the receptor binding domain contained within S1 primarily targeted by current SARS-CoV-2 vaccines. One of these S2-directed mAbs, CC40.8, has demonstrated protective efficacy in small animal models against SARS-CoV-2 challenge. As the next step in the pre-clinical testing of S2-directed antibodies as a strategy to protect from SARS-CoV-2 infection, we evaluated the\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy of CC40.8 in a clinically relevant non-human primate model by conducting passive antibody transfer to rhesus macaques (RM) followed by SARS-CoV-2 challenge. CC40.8 mAb was intravenously infused at 10mg\/kg, 1mg\/kg, or 0.1 mg\/kg into groups (n = 6) of RM, alongside one group that received a control antibody (PGT121). Viral loads in the lower airway were significantly reduced in animals receiving higher doses of CC40.8. We observed a significant reduction in inflammatory cytokines and macrophages within the lower airway of animals infused with 10mg\/kg and 1mg\/kg doses of CC40.8. Viral genome sequencing demonstrated a lack of escape mutations in the CC40.8 epitope. Collectively, these data demonstrate the protective efficiency of broadly neutralizing S2-targeting antibodies against SARS-CoV-2 infection within the lower airway while providing critical preclinical work necessary for the development of pan\u2013\u03b2-CoV vaccines.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1012456","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:33:27Z","timestamp":1737639207000},"page":"e1012456","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques"],"prefix":"10.1371","volume":"21","author":[{"given":"Christopher T.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti A.","family":"Karunakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadj","family":"Aoued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Cole","family":"Honeycutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Lapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thang","family":"Ton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Bombin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Scheuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Dessasau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Paiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Piantadosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiees","family":"Andrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2116-5061","authenticated-orcid":true,"given":"Steven E.","family":"Bosinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"4","key":"ppat.1012456.ref001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.46234\/ccdcw2020.017","article-title":"A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases\u2014Wuhan, China 2019\u20132020","volume":"2","author":"W Tan","year":"2020","journal-title":"China CDC Wkly"},{"issue":"3","key":"ppat.1012456.ref002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"J Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"ppat.1012456.ref003","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses","volume":"24","author":"S Su","year":"2016","journal-title":"Trends Microbiol"},{"issue":"1","key":"ppat.1012456.ref004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tim.2016.09.001","article-title":"Molecular Evolution of Human Coronavirus Genomes","volume":"25","author":"D Forni","year":"2017","journal-title":"Trends Microbiol"},{"issue":"1","key":"ppat.1012456.ref005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12985-015-0439-5","article-title":"MERS coronavirus: diagnostics, epidemiology and transmission","volume":"12","author":"IM Mackay","year":"2015","journal-title":"Virol J"},{"issue":"3","key":"ppat.1012456.ref006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrmicro775","article-title":"SARS\u2014beginning to understand a new virus","volume":"1","author":"K Stadler","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"ppat.1012456.ref007","unstructured":"Organization WH. WHO Coronavirus (COVID-19) Dashboard 2020 [Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c."},{"issue":"27","key":"ppat.1012456.ref008","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"ppat.1012456.ref009","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"ppat.1012456.ref010","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"EJ Anderson","year":"2020","journal-title":"N Engl J Med"},{"issue":"10249","key":"ppat.1012456.ref011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"PM Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"10267","key":"ppat.1012456.ref012","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"MN Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"10249","key":"ppat.1012456.ref013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"F-C Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10269","key":"ppat.1012456.ref014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"7868","key":"ppat.1012456.ref015","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"U Sahin","year":"2021","journal-title":"Nature"},{"issue":"7830","key":"ppat.1012456.ref016","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"U Sahin","year":"2020","journal-title":"Nature"},{"issue":"8","key":"ppat.1012456.ref017","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"J Frater","year":"2021","journal-title":"Lancet HIV"},{"issue":"15","key":"ppat.1012456.ref018","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19","volume":"325","author":"KE Stephenson","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"ppat.1012456.ref019","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"C Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ppat.1012456.ref020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"W Tai","year":"2020","journal-title":"Cell Res"},{"key":"ppat.1012456.ref021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"N Pardi","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"ppat.1012456.ref022","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: Platforms and current developments","volume":"30","author":"GT Szab\u00f3","year":"2022","journal-title":"Mol Ther"},{"issue":"5","key":"ppat.1012456.ref023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ppat.1012456.ref024","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/14760584.2021.1962304","article-title":"COVID-19 vaccines approved in the European Union: current evidence and perspectives","volume":"20","author":"S. Bellino","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"ppat.1012456.ref025","article-title":"EMA recommends COVID-19","author":"EM Agency","year":"2021","journal-title":"Vaccine AstraZeneca for authorisation in the EU"},{"issue":"7","key":"ppat.1012456.ref026","first-page":"1136","article-title":"A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.","volume":"11","author":"N Serra","year":"2023","journal-title":"Nato Adv Sci Inst Se"},{"issue":"8","key":"ppat.1012456.ref027","first-page":"1169","article-title":"Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers","volume":"10","author":"A B\u0142aszczuk","year":"2022","journal-title":"Nato Adv Sci Inst Se"},{"issue":"7","key":"ppat.1012456.ref028","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jit609","article-title":"Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses","volume":"209","author":"S Agnihothram","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"ppat.1012456.ref029","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.","volume":"11","author":"AT Huang","year":"2020","journal-title":"Nat Commun"},{"issue":"637","key":"ppat.1012456.ref030","doi-asserted-by":"crossref","first-page":"eabi9215","DOI":"10.1126\/scitranslmed.abi9215","article-title":"A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.","volume":"14","author":"P Zhou","year":"2022","journal-title":"Sci Transl Med"},{"issue":"13","key":"ppat.1012456.ref031","doi-asserted-by":"crossref","first-page":"108915","DOI":"10.1016\/j.celrep.2021.108915","article-title":"Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients","volume":"34","author":"Y Li","year":"2021","journal-title":"Cell Reports"},{"issue":"1","key":"ppat.1012456.ref032","doi-asserted-by":"crossref","first-page":"100189","DOI":"10.1016\/j.xcrm.2020.100189","article-title":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses","volume":"2","author":"JT Ladner","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"ppat.1012456.ref033","doi-asserted-by":"crossref","first-page":"e162192","DOI":"10.1172\/JCI162192","article-title":"Nierop GPv. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"M Aguilar-Bretones","year":"2023","journal-title":"J Clin Invest"},{"key":"ppat.1012456.ref034","article-title":"Structural basis for broad coronavirus neutralization","author":"MM Sauer","year":"2021","journal-title":"Biorxiv"},{"issue":"1","key":"ppat.1012456.ref035","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"C Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"ppat.1012456.ref036","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"W Dejnirattisai","year":"2022","journal-title":"Cell"},{"issue":"1","key":"ppat.1012456.ref037","doi-asserted-by":"crossref","first-page":"2002106","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"K Leung","year":"2021","journal-title":"Eurosurveillance"},{"issue":"10271","key":"ppat.1012456.ref038","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(21)00144-6","article-title":"South Africa responds to new SARS-CoV-2 variant","volume":"397","author":"M. Makoni","year":"2021","journal-title":"Lancet (Lond, Engl)."},{"issue":"6544","key":"ppat.1012456.ref039","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"NR Faria","year":"2021","journal-title":"Sci (N York, Ny)."},{"issue":"7","key":"ppat.1012456.ref040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-021-01397-4","article-title":"SARS-CoV-2 variants of concern are emerging in India","volume":"27","author":"J Singh","year":"2021","journal-title":"Nat Med"},{"key":"ppat.1012456.ref041","first-page":"95","article-title":"The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity","author":"Y Zhou","year":"2023","journal-title":"J M\u00e9d Virol"},{"issue":"11","key":"ppat.1012456.ref042","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"A Rambaut","year":"2020","journal-title":"Nat Microbiol"},{"issue":"9","key":"ppat.1012456.ref043","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.chom.2022.07.006","article-title":"Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2","volume":"30","author":"C Pastorio","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"3","key":"ppat.1012456.ref044","doi-asserted-by":"crossref","first-page":"taac037","DOI":"10.1093\/jtm\/taac037","article-title":"The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta","volume":"29","author":"Y Liu","year":"2022","journal-title":"J Travel Med"},{"issue":"8","key":"ppat.1012456.ref045","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"BJ Willett","year":"2022","journal-title":"Nat Microbiol"},{"issue":"6506","key":"ppat.1012456.ref046","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.","volume":"369","author":"TF Rogers","year":"2020","journal-title":"Sci (N York, Ny)."},{"issue":"7821","key":"ppat.1012456.ref047","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals.","volume":"584","author":"DF Robbiani","year":"2020","journal-title":"Nature"},{"issue":"1","key":"ppat.1012456.ref048","first-page":"1","article-title":"Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li F. Structure","year":"2015","journal-title":"Annu Rev Virol"},{"issue":"2","key":"ppat.1012456.ref049","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"AC Walls","year":"2020","journal-title":"Cell"},{"issue":"6483","key":"ppat.1012456.ref050","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"D Wrapp","year":"2020","journal-title":"Sci (N York, Ny)."},{"issue":"13","key":"ppat.1012456.ref051","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2021.2088","article-title":"SARS-CoV-2 Viral Variants\u2014Tackling a Moving Target","volume":"325","author":"JR Mascola","year":"2021","journal-title":"JAMA"},{"issue":"7857","key":"ppat.1012456.ref052","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"P Wang","year":"2021","journal-title":"Nature"},{"issue":"7","key":"ppat.1012456.ref053","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"WT Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"ppat.1012456.ref054","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41392-023-01472-x","article-title":"Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.","volume":"8","author":"L Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"ppat.1012456.ref055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Y Chen","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"ppat.1012456.ref056","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","article-title":"Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection","volume":"12","author":"G Song","year":"2021","journal-title":"Nat Commun"},{"issue":"70","key":"ppat.1012456.ref057","doi-asserted-by":"crossref","first-page":"eabo0535","DOI":"10.1126\/sciimmunol.abo0535","article-title":"Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues","volume":"7","author":"CE Nelson","year":"2022","journal-title":"Sci Immunol"},{"issue":"5","key":"ppat.1012456.ref058","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues","volume":"181","author":"CGK Ziegler","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ppat.1012456.ref059","doi-asserted-by":"crossref","first-page":"e1010161","DOI":"10.1371\/journal.ppat.1010161","article-title":"Advances and gaps in SARS-CoV-2 infection models","volume":"18","author":"C Mu\u00f1oz-Fontela","year":"2022","journal-title":"PLoS Pathog"},{"issue":"9","key":"ppat.1012456.ref060","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron","volume":"185","author":"M Gagne","year":"2022","journal-title":"Cell"},{"issue":"2","key":"ppat.1012456.ref061","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","volume":"184","author":"TN Hoang","year":"2021","journal-title":"Cell"},{"issue":"13","key":"ppat.1012456.ref062","doi-asserted-by":"crossref","first-page":"e160039","DOI":"10.1172\/jci.insight.160039","article-title":"mRNA-1273 vaccination protects against SARS-CoV-2\u2013elicited lung inflammation in nonhuman primates","volume":"7","author":"AT Waickman","year":"2022","journal-title":"JCI Insight"},{"issue":"85","key":"ppat.1012456.ref063","doi-asserted-by":"crossref","first-page":"eadg0033","DOI":"10.1126\/sciimmunol.adg0033","article-title":"Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques","volume":"8","author":"EG Viox","year":"2023","journal-title":"Sci Immunol"},{"key":"ppat.1012456.ref064","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41564-020-00841-4","article-title":"Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets","volume":"6","author":"DK Singh","year":"2021","journal-title":"Nat Microbiol."},{"key":"ppat.1012456.ref065","first-page":"11","article-title":"Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates.","author":"MD Fahlberg","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"ppat.1012456.ref066","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cell.2020.10.005","article-title":"Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.","volume":"183","author":"M Aid","year":"2020","journal-title":"Cell"},{"issue":"1","key":"ppat.1012456.ref067","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/s41467-023-37425-9","article-title":"TREM2(+) and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques.","volume":"14","author":"AA Upadhyay","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"ppat.1012456.ref068","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.chom.2020.11.013","article-title":"The immune landscape in tuberculosis reveals populations linked to disease and latency","volume":"29","author":"E Esaulova","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"ppat.1012456.ref069","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Y Yang","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"ppat.1012456.ref070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation.","volume":"20","author":"N Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"16","key":"ppat.1012456.ref071","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"ppat.1012456.ref072","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41594-021-00596-4","article-title":"Structural basis for broad coronavirus neutralization","volume":"28","author":"MM Sauer","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"ppat.1012456.ref073","doi-asserted-by":"crossref","first-page":"637651","DOI":"10.3389\/fimmu.2021.637651","article-title":"The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic","volume":"12","author":"P Shah","year":"2021","journal-title":"Front Immunol"},{"key":"ppat.1012456.ref074","doi-asserted-by":"crossref","first-page":"720109","DOI":"10.3389\/fimmu.2021.720109","article-title":"Monocytes and Macrophages in COVID-19","volume":"12","author":"R Knoll","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"ppat.1012456.ref075","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41467-022-28315-7","article-title":"Myeloid cell interferon responses correlate with clearance of SARS-CoV-2.","volume":"13","author":"DK Singh","year":"2022","journal-title":"Nat Commun"},{"issue":"662","key":"ppat.1012456.ref076","doi-asserted-by":"crossref","first-page":"eabn5168","DOI":"10.1126\/scitranslmed.abn5168","article-title":"A shift in lung macrophage composition is associated with COVID-19 severity and recovery","volume":"14","author":"ST Chen","year":"2022","journal-title":"Sci Transl Med"},{"key":"ppat.1012456.ref077","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions.","volume":"5","author":"G Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"ppat.1012456.ref078","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3390\/ijms22052284","article-title":"Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.","volume":"22","author":"H Wei","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ppat.1012456.ref079","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave","volume":"29","author":"ST Tan","year":"2023","journal-title":"Nat Med"},{"issue":"6585","key":"ppat.1012456.ref080","doi-asserted-by":"crossref","first-page":"eabl4292","DOI":"10.1126\/science.abl4292","article-title":"Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel","volume":"375","author":"O Prunas","year":"2022","journal-title":"Science"},{"issue":"5","key":"ppat.1012456.ref081","doi-asserted-by":"crossref","first-page":"e2213606","DOI":"10.1001\/jamanetworkopen.2022.13606","article-title":"Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals","volume":"5","author":"J Jung","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ppat.1012456.ref082","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41467-022-28199-7","article-title":"Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections","volume":"13","author":"LJ Abu-Raddad","year":"2022","journal-title":"Nat Commun"},{"key":"ppat.1012456.ref083","doi-asserted-by":"crossref","first-page":"e70458","DOI":"10.7554\/eLife.70458","article-title":"SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19","volume":"10","author":"PZ Chen","year":"2021","journal-title":"eLife"},{"issue":"9","key":"ppat.1012456.ref084","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1473-3099(21)00406-0","article-title":"Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic","volume":"21","author":"PZ Chen","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ppat.1012456.ref085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(20)30985-3","article-title":"Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study","volume":"21","author":"M Marks","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ppat.1012456.ref086","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41467-020-20568-4","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).","volume":"12","author":"Vijver DAMCvd Kampen JJAv","year":"2021","journal-title":"Nat Commun"},{"key":"ppat.1012456.ref087","doi-asserted-by":"crossref","first-page":"1296603","DOI":"10.3389\/fimmu.2023.1296603","article-title":"Detection of anti-SARS-CoV-2 salivary antibodies in vaccinated adults","volume":"14","author":"VT Castro","year":"2023","journal-title":"Front Immunol."},{"key":"ppat.1012456.ref088","doi-asserted-by":"crossref","first-page":"933347","DOI":"10.3389\/fimmu.2022.933347","article-title":"Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA","volume":"13","author":"M Stolovich-Rain","year":"2023","journal-title":"Front Immunol."},{"issue":"4","key":"ppat.1012456.ref089","first-page":"100129","article-title":"SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.","volume":"2","author":"KT Cao","year":"2023","journal-title":"J Allergy Clin Immunol: Glob"},{"issue":"4","key":"ppat.1012456.ref090","doi-asserted-by":"crossref","first-page":"e248051","DOI":"10.1001\/jamanetworkopen.2024.8051","article-title":"Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.","volume":"7","author":"G Gorochov","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"ppat.1012456.ref091","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40121-022-00753-2","article-title":"Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review","volume":"12","author":"N Pooley","year":"2023","journal-title":"Infect Dis Ther."},{"key":"ppat.1012456.ref092","doi-asserted-by":"crossref","first-page":"e069052","DOI":"10.1136\/bmj-2021-069052","article-title":"Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study","volume":"376","author":"M Fabiani","year":"2022","journal-title":"BMJ"},{"issue":"7923","key":"ppat.1012456.ref093","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Q Wang","year":"2022","journal-title":"Nature"},{"issue":"10328","key":"ppat.1012456.ref094","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"DR Feikin","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"ppat.1012456.ref095","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jama.2022.2068","article-title":"Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance","volume":"327","author":"A Britton","year":"2022","journal-title":"JAMA"},{"issue":"18","key":"ppat.1012456.ref096","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a Fourth Dose of BNT162b2 against Omicron in Israel","volume":"386","author":"YM Bar-On","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1012456.ref097","doi-asserted-by":"crossref","first-page":"e071113","DOI":"10.1136\/bmj-2022-071113","article-title":"Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study","volume":"377","author":"S Gazit","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"ppat.1012456.ref098","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent Omicron BA.1\u2013Adapted BNT162b2 Booster in Adults Older than 55 Years","volume":"388","author":"P Winokur","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"ppat.1012456.ref099","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1473-3099(23)00374-2","article-title":"Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study","volume":"23","author":"A Mateo-Urdiales","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"ppat.1012456.ref100","first-page":"ciad718","article-title":"A Bivalent Omicron-BA.4\/BA.5-Adapted BNT162b2 Booster in \u226512-Year-Olds","author":"L Usdan","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ppat.1012456.ref101","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","article-title":"Predicting the efficacy of variant-modified COVID-19 vaccine boosters","volume":"29","author":"DS Khoury","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"ppat.1012456.ref102","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41423-020-00523-5","article-title":"Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients","volume":"17","author":"Y Li","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"ppat.1012456.ref103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB","volume":"388","author":"M Imai","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"ppat.1012456.ref104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Q Wang","year":"2023","journal-title":"Cell"},{"issue":"22","key":"ppat.1012456.ref105","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1056\/NEJMc2211845","article-title":"In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6","volume":"387","author":"E Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"ppat.1012456.ref106","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S1473-3099(22)00694-6","article-title":"Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation","volume":"22","author":"Q Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ppat.1012456.ref107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants","volume":"387","author":"E Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1012456.ref108","article-title":"Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab.","author":"Administration FaD.","year":"2022"},{"key":"ppat.1012456.ref109","article-title":"Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab).","author":"Administration FaD.","year":"2023"},{"key":"ppat.1012456.ref110","article-title":"Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of bebtelovimab","author":"Administration FaD.","year":"2022"},{"issue":"25","key":"ppat.1012456.ref111","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2202861","article-title":"SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients","volume":"386","author":"EM Scherer","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1012456.ref112","article-title":"New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19","author":"A. Bock","year":"2024","journal-title":"JAMA"},{"key":"ppat.1012456.ref113","article-title":"Drug. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of PEMGARDA (pemivibart) for Coronavirus Disease 2019 (COVID-19).","author":"F Administration"},{"key":"ppat.1012456.ref114","doi-asserted-by":"crossref","first-page":"104915","DOI":"10.1016\/j.compbiomed.2021.104915","article-title":"Understanding mutation hotspots for the SARS-CoV-2 spike protein using Shannon Entropy and K-means clustering","volume":"138","author":"B Mullick","year":"2021","journal-title":"Comput Biol Med"},{"issue":"1","key":"ppat.1012456.ref115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/v14010077","article-title":"Intra-Host SARS-CoV-2 Evolution in the Gut of Mucosally-Infected Chlorocebus aethiops (African Green Monkeys).","volume":"14","author":"LA Rowe","year":"2022","journal-title":"Viruses"},{"key":"ppat.1012456.ref116","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.lanepe.2021.100164","article-title":"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.","volume":"8","author":"B Jensen","year":"2021","journal-title":"Lancet Reg Heal\u2014Eur"},{"issue":"2","key":"ppat.1012456.ref117","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiae192","article-title":"Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2","volume":"230","author":"MC Choudhary","year":"2024","journal-title":"J Infect Dis"},{"issue":"88","key":"ppat.1012456.ref118","article-title":"Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques.","volume":"8","author":"VJ Munster","year":"2023","journal-title":"Sci Immunol"},{"key":"ppat.1012456.ref119","first-page":"7","article-title":"Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates","author":"NK Routhu","year":"2021","journal-title":"Science Advances"},{"issue":"3","key":"ppat.1012456.ref120","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2023.02.005","article-title":"Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease","volume":"56","author":"P Zhou","year":"2023","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1012456","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:42:09Z","timestamp":1738676529000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012456"}},"subtitle":[],"editor":[{"given":"Xiu-Feng","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012456","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}